Lataa...
A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma
PURPOSE: The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097, an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in patients with advanced solid tumors. We aimed to evaluate the efficacy of RO4929097 in patients with pancreatic adenocarcinoma (...
Tallennettuna:
| Julkaisussa: | Invest New Drugs |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4292847/ https://ncbi.nlm.nih.gov/pubmed/24668033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0083-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|